Paper
Activity and unexpected lung toxicity of the sequential administration of two alkylating agents—Dacarbazine and fotemustine—in patients with melanoma

https://doi.org/10.1016/S0959-8049(05)80352-1Get rights and content

We report the results and discuss the toxicity of clinical trials based on a single concept: the decrease in O6alkyl DNA alkyltransferase (O6AT) resistance mechanism when a chloroethylating agent is used sequentially after a methylating agent. This decrease in O6AT being dose dependent, several increasing doses of dacarbazine (DTIC) have been tested (400 mg/m2 to 1000 mg/m2 every 4 weeks, 3–4 h before fotemustine (100 mg/m2 intravenously every 4 weeks). These results (mean overall response rate 27%) compared with reference regimes, demonstrate that DTIC is able to increase the alkylating power of fotemustine: same range of response rate with only half of the two drug doses compared to an alternated combination, high activity rate especially in lung metastases (10/42 complete responses + 13/42 partial responses), different pattern for haematotoxicity, and occurrence of a new side-effect: acute lung toxicity as adult respiratory distress syndrome (ARDS). This lung toxicity was totally unexpected since several hundreds of patients had been so far treated with fotemustine as single agent or in other combinations with DTIC without any case of acute or delayed lung toxicity. Prophylactic administration of corticoids was not effective and monitoring of the respiratory function was of no predictive value. Due to the additional depleting effects of DTIC on at least two main defence mechanisms—the O6AT system and cytosolic and/or nuclear glutathione—we suppose that the sequence is able to increase the alkylating power of fotemustine to an excessive extent and/or that the detoxication capacity of the cell against DTIC and/or fotemustine metabolites is overwhelmed. Other depletors of the O6AT activity which do not generate metabolites that compete for the same detoxication pathway as the chloroethylnitrosurea (CENU) metabolites should be tested.

References (44)

  • BrentTP et al.

    O6 Alkylguanine DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea

  • EricksonLC et al.

    DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells

    Nature

    (1980)
  • BodellWJ et al.

    Increased repair of O6 alkylguanine DNA adducts in glioma derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea

    Carcinogenesis

    (1986)
  • LindahlT et al.

    Suicide inactivation of the E. coli O6 methyl-guanine DNA methyltansferase

    EMBO J

    (1982)
  • MulcahyRT

    Misonidazole-induced chemopotentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea toxicity in O6-methylguanine-DNA methyltransferase proficient (Mer+) and deficient (Mer−) cell lines

    Cancer Res

    (1986)
  • DolanME et al.

    Effect of O6 alkylguanine pretreatment on the sensitivity of human colon tumour cells to the cytotoxic effects of chloroethylating agents

    Cancer Res

    (1986)
  • EriksonLG et al.

    Pretreatment of human tumour cells with streptozotocin (STZ, NSC-85998) can inhibit DNA repair processes which prevent DNA interstrand crosslinking by BCNU (NSC-409962): possible clinical applications for the sensitization of resistant tumours to chemotherapy (Meeting Abstract). International Conference on Mechanisms of DNA Damage and Repair

  • JacquillatC et al.

    Final report of the French multicenter phase II study of the nitrosourea Fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

    Cancer

    (1990)
  • D'IncalciM et al.

    O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia

    Anticancer Res

    (1991)
  • LeeSM et al.

    O6-alkylguanine-DNA alkyl-transferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine

    Cancer Res

    (1991)
  • AvrilMF et al.

    Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French study group

    Cancer Chemother Pharmacol

    (1990)
  • GinsbergSJ et al.

    The pulmonary toxicity of antineoplastic agents

    Sem Oncol

    (1982)

    • Cited by (52)

    • New toxicity of fotemustine: Diffuse interstitial lung disease

      2012, Annales de Dermatologie et de Venereologie

    • Targeting DNA repair pathways: A novel approach to reduce cancer therapeutic resistance

      2009, Cancer Treatment Reviews
      Citation Excerpt :

      Therefore, substantial MGMT depletion is achieved with use of multiple doses of drugs given at special intervals. However, such a protocol might increase the risk of bone marrow and lung toxicity relative to standard protocols.21,47,48 For example, for trials in which streptozotocin was used to enhance the cytotoxicity of BCNU, excessive systemic toxicity was reported during Phase I, and limited response rates were seen during Phase II.19

    • Targeting DNA repair as a promising approach in cancer therapy

      2007, European Journal of Cancer
      Citation Excerpt :

      The most likely reason for the lack of these studies is related to the fact that in small pilot studies the bone marrow toxicity appeared to be higher than expected with sequential combinations.8,37,40 A further reported drawback was related to lung toxicity (manifested as interstitial pneumonitis) that was shown in patients receiving sequential treatment with dacarbazine and nitrosoureas.41,42 A weak aspect of most published studies is that most information was obtained by determining the enzyme level in lymphocytes,8,37 that does not necessarily reflect what happens in the tumour.

    • Temozolomide-associated organizing pneumonitis

      2007, Mayo Clinic Proceedings
      Citation Excerpt :

      Numerous alkylating agents including cyclophosphamide, busulfan, and chlorambucil3 have been clearly associated with pulmonary adverse reactions. Dacarbazine, an alkylating agent closely related to temozolomide, has been associated with pulmonary toxicity only when used in combination with fotemustine, a nitrosourea agent.4 Approved by the Food and Drug Administration in 1999, temozolomide is a second-generation oral alkylating agent.

    • Role of O<sup>6</sup>-methylguanine-DNA methyltransferase and effect of O<sup>6</sup>-benzylguanine on the anti-tumor activity of cis- diaminedichloroplatinum(II) in oral cancer cell lines

      2005, Oral Oncology

    • Metastatic melanoma: Chemotherapy

      2002, Seminars in Oncology
      Citation Excerpt :

      In sequential schedules, DTIC was administered 3 to 4 hours before FTMU, in an attempt to achieve a synergistic effect by depleting O6-alkyltransferase, the enzyme responsible for the resistance to nitrosourea. Despite convincing clinical efficacy, this schedule was compromised by unexpected fatal lung toxicity.58-60 To avoid this life-threatening pulmonary side effect, an adjusted sequential regimen with lower doses of DTIC was used in 63 patients.

    View all citing articles on Scopus
    View full text
    Copyright © 1993 Published by Elsevier Ltd.